Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

US-based pharmaceutical company Eli Lilly is planning to launch Mounjaro, an anti-diabetes and weight loss drug in India by 2025 after regulatory approvals, reported News18 citing officials from ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.

President of Lilly Diabetes and Obesity and President of Lilly USA; Eli Lilly and Co Anne White; Executive Vice President, President - Lilly Neuroscience; Eli Lilly and Co Good morning.

Eli Lilly (NYSE:LLY) on Thursday reported its Q4 ... LLY’s GLP-1 therapy tirzepatide, branded as Mounjaro and Zepbound for diabetes and weight loss, respectively, powered the company’s Q4 ...